TARGETED GENETICS "IMPROVED" CD8 CELL HIV GENE THERAPY TRIAL
Executive Summary
TARGETED GENETICS "IMPROVED" CD8 CELL HIV GENE THERAPY TRIAL will be the subject of an IND filing in "early 1995," the company said in a prospectus for an initial public offering. The company plans to design a trial testing CD8 cytotoxic T lymphocyte clones that have been modified to proliferate and attack HIV-infected cells without assistance from CD4 helper cells, the March 30 prospectus states.